Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4126035 | 0.85 | ELANE (0.74) | ELANE | |
| SCHEMBL560680 | 0.85 | ELANE (0.74) | ELANE | |
| Alvelestat SCHEMBL30179302 | 0.84 | ELANE (1.00) | ELANE | |
| Alvelestat SCHEMBL29740084 | 0.84 | ELANE (1.00) | ELANE | |
| Alvelestat SCHEMBL29519811 | 0.84 | ELANE (1.00) | ELANE | |
| Alvelestat SCHEMBL560757 | 0.84 | ELANE (1.00) | ELANE | |
| SCHEMBL4134848 | 0.83 | ELANE (0.70) | ELANE | |
| SCHEMBL25359179 | 0.82 | ELANE (0.83) | ELANE | |
| SCHEMBL31495992 | 0.82 | ELANE (0.70) | ELANE | |
| SCHEMBL4022133 | 0.82 | ELANE (0.70) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190723-A1 | METHODS INVOLVING NEUTROPHIL ELASTASE INHIBITOR ALVELESTAT FOR TREATING RESPIRATORY DISEASE MEDIATED BY ALPHA-1 ANTITRYPSIN DEFICIENCY | MEREO BIOPHARMA 4 LIMITED (GB) | 2023-06-22 | — | — | US | disclosed |
| EP-4106757-A1 | METHODS INVOLVING NEUTROPHIL ELASTASE INHIBITOR ALVELESTAT FOR TREATING RESPIRATORY DISEASE MEDIATED BY ALPHA-1 ANTITRYPSIN DEFICIENCY | Mereo Biopharma 4 Limited (GB) | 2022-12-28 | — | — | EP | disclosed |
| WO-2021209739-A1 | METHODS INVOLVING NEUTROPHIL ELASTASE INHIBITOR ALVELESTAT FOR TREATING RESPIRATORY DISEASE MEDIATED BY ALPHA-1 ANTITRYPSIN DEFICIENCY | MEREO BIOPHARMA 4 LIMITED (GB) | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190723-A1 | METHODS INVOLVING NEUTROPHIL ELASTASE INHIBITOR ALVELESTAT FOR TREATING RESPIRATORY DISEASE MEDIATED BY ALPHA-1 ANTITRYPSIN DEFICIENCY | SERPINB1, ELANE, SERPINA2 | ELANE 2/4885NAMPT 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.